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Background: Cancer-specific survival estimates rely on precise and correct data on the cause of death; however,
these data can be difficult to acquire, particularly in elderly patients where comorbidity is common. Furthermore,
while some deaths are directly related to cancer, others are more complex, with cancer merely contributing.
Another, more precise, method is to assess the relative mortality, i.e., mortality in patients compared to the general
population. The aims of this study were to describe the relative mortality in soft tissue sarcoma, and to compare
the relative mortality with the cancer-specific mortality.
Methods: We included 1246 patients treated for soft tissue sarcoma and 6230 individually age- and sex-matched
individuals from the general population. The relative mortality was estimated as rates, and rate ratios adjusted for
comorbidity. Mortality rate ratios were computed using the Cox proportional hazard model for 0–5 years and 5–10
years, according to age, sex and level of comorbidity. The cancer-specific mortality was compared to the
corresponding relative mortality.
Results: The overall 5- and 10-year relative mortality was 32.8% and 36.0%. Patients with low-grade soft tissue
sarcoma did not have increased mortality compared with the general population. Soft tissue sarcoma patients had
a 4.4 times higher risk of dying within the first five years after diagnosis and a 1.6 times higher risk between five
and ten years compared with the general comparison cohort. The relative mortality varied according to age, grade,
stage at diagnosis, and level of comorbidity, being highest in younger patients and in patients without comorbidity.
The overall 5- and 10-year cancer-specific mortality was underestimated by 1.5 and overestimated by 0.7 percentage
points compared to the relative mortality, respectively. No statistical significant difference between the relative and
the cancer-specific mortality was found.
Conclusion: The relative mortality provides an unbiased and accurate method to differentiate between
cancer-specific and non-cancer-specific deaths. However, when data on the cause of death is of a sufficient quality,
there is no difference between relative mortality and disease-specific mortality based on death certificates.
Keywords: Soft tissue sarcoma, Relative survival, Prognosis, Cancer-specific survival, ComorbidityBackground
The mortality among soft tissue sarcoma patients has
been studied numerous times [1-7]. While some studies
report mortality as overall, most use cancer-specific mea-
sures, since this is expected to better reflect the “true”
mortality caused by the sarcoma [2-7]. However, using
cancer-specific measures entails two potential problems;* Correspondence: k.maretty@dadlnet.dk
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article, unless otherwise stated.misclassification of the underlying cause of death, and no
consensus on which causes of death are related to the
cancer.
Assessing cancer-specific mortality relies on precise
and correct data on the cause of death; however, these
data can be difficult to achieve, particularly in elderly pa-
tients where comorbidity is common. An autopsy re-
mains the best method to determine the cause of death;
however, the autopsy rate in Denmark has declined rap-
idly, as observed in most countries [8-10]. The cause of
death is therefore often registered by physicians, eitherCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and the validity of the registered cause of death is thus
dependent on the physicians’ knowledge of preceding
diseases. Previous studies have concluded that causes of
death are associated with issues of inaccuracy and sub-
stantial variability of coding according to cancer type,
age at death and time period [8,11-16]. Furthermore,
while some deaths are directly related to cancer, others
are more complex, with cancer merely contributing to
the death [17]. In these cases, assigning death as either
cancer-specific or not can be problematic and ambiguous.
Another method to obtain the “true” mortality caused
by the cancer is by assessing the relative mortality, i.e.,
the mortality in cancer patients compared with the mor-
tality in a general population without cancer [18]. The
mortality in the general population can be determined
using life tables or randomly selected individual age- and
sex-matched controls, a unique possibility in Denmark.
Cancer-specific estimates based on death certificates
have been compared to relative estimates in other can-
cers and disease types, with varying results; however, the
correlation between the relative and the disease-specific
mortality has, to our knowledge, not previously been in-
vestigated in soft tissue sarcoma [19,20].
The aims of this study were therefore to estimate the
relative mortality in patients with soft tissue sarcoma
using an age- and sex-matched general comparison co-
hort, as well as to compare the relative mortality with
the cancer-specific mortality based on death certificates.
Methods
Setting
This cohort study was conducted in western Denmark
within a population of approximately 2.5 million [21].
The public health care system in Denmark is tax-funded
and free of charge, allowing free access to hospital care
for all citizens. All residents in Denmark are assigned a
unique 10-digit number, the CPR number, which is used
throughout Danish society, including the health care
system. This allows for linkage on an individual level be-
tween registries.
Data sources
The Aarhus Sarcoma Registry is a population-based regis-
try including all sarcoma patients in western Denmark
treated at the Aarhus Sarcoma Centre from 1st January
1979 to 31th December 2008. The registry has previously
been systematically validated, and contains basic patient
data including date of diagnosis, and detailed data on
tumour characteristics, treatment, and follow-up [22].
The Danish Civil Registration System holds information
on all residents in Denmark since 1968 and is updated on
a daily basis. The registry encompasses both historical
and current data, including CPR number, municipalityof residence, vital status, as well as date of birth, emigra-
tion, and/or death [23].
The Danish National Patient Registry has collected
data on all non-psychiatric admissions to Danish hospi-
tals since 1977, including visits to hospital outpatient
clinics and emergency rooms since 1995. For each me-
dical contact the CPR number, date of admission and
discharge, as well as up to 20 discharge diagnoses is re-
corded. The discharge diagnoses are coded by physicians
according to the eighth (before 1994) and tenth ver-
sion of the International Classification of Disease (ICD-8
and ICD-10), and include both main and secondary
diagnoses [24-27].
The Danish Cause of Death Registry contains data on
the immediate and underlying cause of death, according
to the ICD-8 and ICD-10, based on the diagnosis from
the death certificates. The completion of death certifi-
cates for any death occurring in Denmark is mandatory,
and data has been registered since 1875 [28].
Soft tissue sarcoma patients
The Aarhus Sarcoma Registry was used to identify all
soft tissue sarcoma patients in western Denmark diag-
nosed between 1979 and 2008 (N = 1753). In this study
we focused on patients with tumours located in the ex-
tremities or trunk wall, and therefore 455 patients with
tumours located, e.g., retroperitoneally, intraabdominally,
or in the head and neck, were excluded. Furthermore,
patients (N = 52) with specific histological subtypes tra-
ditionally not considered as a classical soft tissue sar-
coma, e.g., gastrointestinal stromal tumours, kaposis
sarcoma, atypical fibroxanthoma, and atypical lipoma-
tous tumours were excluded, leaving 1246 patients for
the analysis.
Patients at the Aarhus Sarcoma Centre are diagnosed
and treated by an experienced multidisciplinary team,
according to international and national guidelines [29,30].
Sarcomas were classified using the grading system de-
scribed by Jensen et al. [31]. In general, most patients were
treated with surgery, with the aim of a wide margin,
followed by radiotherapy for deep intermediate and high-
grade tumours [32].
General comparison cohort
A random general comparison cohort was sampled from
the general population by individual matching using the
Civil Registration System [23]. For each soft tissue sar-
coma patient registered in the Aarhus Sarcoma Registry
we identified 5 age- and sex-matched individuals from
the general population, who were alive at the date of
sarcoma diagnosis (index date), had not previously been
diagnosed with a sarcoma, and lived in the same geo-
graphical area as the soft tissue sarcoma patient (the
same county).
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Data on comorbidity in both the soft tissue sarcoma pa-
tients and the general comparison cohort was obtained
by individual linkage (CPR number) with the National
Patient Registry [24,27]. All discharge diagnoses between
1st January 1977 and the date of diagnosis (index date)
were retrieved. We excluded all discharge diagnoses
within 30 days, and all cancer diagnoses within 90 days
prior to the date of diagnosis in the soft tissue sarcoma
patients, to eliminate nonspecific symptoms or hospitals
admissions related to the sarcoma. Comorbidity was
assessed using the Charlson Comorbidity Index [33].
The ICD codes used to determine the Charlson Comor-
bidity Index score are shown in an additional table [See
Additional file 1: Table S1].
Statistical analyses
Baseline characteristics were summarized as medians
and interquartile ranges for continuous variables, and
numbers and percentages for categorical variables. The
prevalence of comorbidity in the soft tissue sarcoma pa-
tients and the general comparison cohort was compared
using the chi-squared test. All individuals were followed
from index date to date of death, emigration, or end of
the study (15th July 2013). Data on death were obtained
from the Civil Registration System. The main outcome
measure assessed was relative mortality, computed as
one minus the relative survival (Sr), where the relative
survival [18] is defined as the ratio of the observed over-
all survival of soft tissue sarcoma patients (So) and the
observed survival in the age- and sex matched general
comparison cohort (Se):
Sr ¼ SoSe
The relative mortality was estimated as relative morta-
lity rates (RMRs) and mortality rate ratios (MRRs). The
overall mortality was estimated for soft tissue sarcoma
patients and the general comparison cohort separately,
using the Kaplan-Meier method [34], and the 10-year
RMRs with 95% confidence intervals (CIs) were compu-
ted. RMRs were computed both as overall and according
to histological grade and subtypes. MRRs were estimated
as hazard ratios, using a Cox proportional hazard model,
adjusting for age, sex, and level of comorbidity [35]. Age
and comorbidity were included, as seen in Table 1. Age,
sex, comorbidity, and time-specific estimates were com-
puted. To estimate the impact of treatment, stage-specific
MRRs were computed using a model adjusting for age,
comorbidity, compartmentalization, depth, grade, histo-
logical type, location, and size. The adjustment covariates
were selected based on a modified version (Figure 1) of a
directed acyclic graph constructed by Maretty-Nielsenet al. [36,37] and included as seen in Tables 1 and 2. The
proportional hazard assumption was assessed graphically
using log-log plots. Based on this it was found that the as-
sumption was not met and MRRs were therefore analysed
separately from 0–5 years and from 5–10 years. No viola-
tion of the proportional hazard assumption was found
within these follow-up periods.
The cancer-specific mortality included all deaths from
sarcoma or deaths with metastatic sarcoma. A death was
considered as cancer-specific if the medical files ren-
dered the death likely to be a consequence of the soft
tissue sarcoma, e.g., death of a patient with multiple lung
metastases and evident pneumonia. Data on the cause of
death were retrieved from the Aarhus Sarcoma Registry
and the Danish Cause of Death Registry. The cancer-
specific mortality rate was estimated using the Kaplan-
Meier method. The 5- and 10-year cancer-specific mortality
was compared to the corresponding RMR for the entire
soft tissue sarcoma cohort as well as according to stage at
diagnosis.
All tests were two-sided and a p-value ≤ 0.05 was con-
sidered significant. Analyses were performed using the
statistical software Stata, version 11.2.
Ethics
The study was approved by the Danish Data Protection
Agency, the Danish Health and Medicines Authority,
and the National Committee on Health Research Ethics.
Results
Descriptive data
We identified 1246 soft tissue sarcoma patients and
6230 general comparison cohort individuals. The soft tis-
sue sarcoma patient characteristics are shown in Table 2.
The most frequent histological types of soft tissue sarcoma
were malignant fibrous histiocytoma (300 [24.1%]), lipo-
sarcoma (195 [15.7%]), and leiomyosarcoma (190 [15.3%]).
The prevalence of comorbidity in soft tissue sarcoma pa-
tients and the general comparison cohort is shown in
Table 3. The prevalence of the various medical conditions
was comparable, except for ‘any tumour’ and ‘metastatic
solid tumour’. The prevalence of ‘Any tumour’ was 1.9
times (95% CI: 1.5-2.3) higher and ‘metastatic solid tu-
mour’ was 7.3 times (95% CI: 4.2-12.5) higher in the soft
tissue sarcoma patients, compared to the general compari-
son cohort. The median follow up period was 6.6 years
(interquartile range 1.7-13.7) in soft tissue sarcoma pa-
tients and 11.2 years (interquartile range 6.8-17.7) in the
general comparison cohort.
Overall mortality
In total, 735 (59.0%) of the soft tissue sarcoma patients
and 2265 (36.4%) of the general comparison cohort died
during the follow-up period. The overall mortality for
Table 1 Overall mortality and mortality rate ratios at diagnosis/index date for soft tissue sarcoma patients (N = 1246)
and the general comparison cohort (N = 6230)
STS patient
mortality % (95% CI)
General comparison





0 to 5 years
Gender Female 40.2 (36.4-44.3) 10.7 (9.7-11.9) 4.8 (4.1-5.7) 4.7 (3.9-5.6)
Male 41.6 (37.9-45.5) 13.5 (12.4-14.7) 3.9 (3.4-4.6) 4.2 (3.6-4.9)
Age (years) 0-39 27.2 (22.5-32.7) 0.3 (0.1-0.7) 116.7 (42.7-318.6) 110.8 (40.5-303.0)
40-59 24.4 (20.3-29.2) 2.4 (1.8-3.3) 11.5 (8.0-16.4) 11.0 (7.6-15.8)
60-79 53.9 (49.5-58.5) 16.5 (15.1-18.1) 4.7 (4.0-5.5) 4.4 (3.7-5.1)
≥ 80 72.2 (64.3-79.6) 51.2 (47.4-55.1) 1.9 (1.5-2.4) 1.9 (1.5-2.4)
Comorbidity None 34.9 (31.9-38.0) 7.0 (6.3-7.8) 6.2 (5.4-7.2) 6.6 (5.7-7.7)
Low 52.3 (43.3-62.0) 24.3 (21.2-27.8) 2.9 (2.1-3.9) 3.0 (2.2-4.1)
Moderate 60.6 (51.5-69.7) 34.2 (29.7-39.2) 2.5 (1.9-3.4) 2.8 (2.1-3.8)
High 68.7 (58.8-78.2) 48.9 (43.0-55.3) 1.8 (1.3-2.4) 2.0 (1.4-2.7)
Total 41.0 (38.3-43.7) 12.2 (11.4-13.0) 4.3 (3.8-4.8) 4.4 (3.9-4.9)
5 to 10 years
Gender Female 16.0 (12.3-20.6) 11.7 (10.4-13.1) 1.4 (1.1-2.0) 1.8 (1.3-2.5)
Male 19.2 (15.4-23.9) 15.2 (13.8-16.7) 1.3 (1.0-1.7) 1.5 (1.2-2.0)
Age (years) 0-39 8.1 (5.1-13.0) 0.8 (0.4-1.4) 11.1 (5.1-24.6) 11.1 (5.0-24.6)
40-59 12.4 (8.8-17.3) 4.4 (3.5-5.6) 3.1 (2.0-4.8) 2.9 (1.8-4.4)
60-79 28.4 (22.3-35.8) 24.3 (22.2-26.5) 1.2 (0.9-1.6) 1.2 (0.9-1.6)
≥ 80 60.0 (42.8-77.7) 64.0 (57.9-70.0) 1.0 (0.6-1.7) 1.1 (0.7-1.7)
Comorbidity None 13.7 (11.1-16.9) 11.1 (10.1-12.2) 1.4 (1.1-1.8) 1.5 (1.2-2.0)
Low 41.3 (26.5-60.4) 23.0 (18.8-27.9) 1.3 (0.8-2.3) 1.6 (0.9-2.8)
Moderate 44.9 (30.6-62.3) 23.9 (19.9-28.6) 1.9 (1.1-3.3) 2.8 (1.6-4.9)
High 32.9 (17.8-55.7) 20.1 (15.6-25.6) 0.7 (0.3-1.5) 0.9 (0.4-2.0)
Total 17.7 (14.9-20.9) 13.5 (12.5-14.5) 1.4 (1.1-1.7) 1.6 (1.3-2.0)
NOTES: Abbreviations: STS soft tissue sarcoma, MRR mortality rate ratio, CI confidence interval. *Adjusted for age, gender, and level of comorbidity.
Figure 1 Directed acyclic graph of the possible relationship between important covariates and mortality in soft tissue sarcoma patients.
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Table 2 Clinico-pathological characteristics of soft tissue
sarcoma patient (N = 1246)
N %
Age (years) Median (interquartile range) 58 (41–71)
Gender Female 587 47.1
Male 659 52.9
Stage at diagnosis Localized 1098 88.1
Metastatic 148 11.9
Location Upper extremity 190 15,3
Trunk 447 35.9
Lower extremity 603 48.4
Disseminated/unknown 6 0.5
Depth Subcutaneus 374 30.0
Subfascial 872 70.0
Tumour size (cm)a < 5 410 33.7
5-9 394 32.4
≥ 10 411 33.8
Histological grade Low 223 17.9
Intermediate 168 13.5
High 855 68.6
Treatment Surg 773 62.0
Surg + Rt 299 24.0
Surg + Ch 45 3.6
Surg + Rt + Ch 48 3.9
Rt 17 1.4
Ch 14 1.1
Rt + Ch 20 1.6
None 30 2.4
NOTES: Abbreviations: Surg surgery, Rt radiotherapy, Ch chemotherapy.
a31 missing values.
Table 3 Comorbidity in soft tissue sarcoma patients
(N = 1246) and the general comparison cohort (N = 6230)







Myocardial infarct 44 (3.5) 188 (3.0) 0.34
Congestive heart failure 22 (1.8) 133 (1.8) 0.91
Peripheral vascular
disease
27 (2.2) 100 (1.6) 0.16
Cerebrovascular disease 44 (3.5) 259 (4.2) 0.31
Dementia 5 (0.4) 39 (0.6) 0.34
Chronic pulmonary
disease
47 (3.8) 259 (4.2) 0.53
Connective tissue
disease
18 (1.4) 97 (1.6) 0.77
Ulcer disease 37 (3.0) 167 (2.7) 0.57
Mild liver disease 7 (0.6) 31 (0.5) 0.77
Diabetes 33 (2.7) 164 (2.6) 0.97
Hemiplegia 1 (0.1) 4 (0.1) 0.84
Moderate/severe renal
disease
11 (0.9) 39 (0.6) 0.31
Diabetes with end
organ damage
7 (0.6) 67 (1.1) 0.10
Any tumour* 121 (9.7) 323 (5.2) <0.001
Leukemia 4 (0.3) 9 (0.1) 0.17
Lymphoma 5 (0.4) 14 (0.2) 0.26
Moderate/severe liver
disease
0 (0.0) 6 (0.1) 0.27
Metastatic solid tumour 32 (2.6) 22 (0.4) <0.001
AIDS 0 (0.0) 3 (0.1) 0.44
NOTES: Abbreviations: STS soft tissue sarcoma, AIDS acquired
immunedeficiency syndrome. †Chi-squared test. *Excluding tumour in soft
tissue and bone (ICD-8; 170, 171, 192.49-99 and ICD-10; C40-C41, C47, C49).
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parison cohort is shown in Figure 2. The mortality for
soft tissue sarcoma patients was higher than that of the
general comparison cohort during the entire follow-up
period. The 5- and 10-year overall mortality were 41.0%
(95% CI: 38.3-43.8) and 51.4% (95% CI: 48.6-54.3) for
soft tissue sarcoma patients compared with 12.2% (95%
CI: 11.4-13.0) and 24.0% (95% CI: 22.9-25.2) for the
general comparison cohort, respectively. 70% of the ob-
served deaths in soft tissue sarcoma patients within five
years and 53% within ten years were related to the soft
tissue sarcoma.Relative mortality
The overall RMR are shown in Figure 2b. The mortality
was not significantly increased in patients with low grade
soft tissue sarcoma compared to the general comparison
cohort, as seen in Figure 3a. The mortality was increased
in patients with intermediate and high grade soft tissuesarcoma; however, while the increase in mortality was
constant for intermediate soft tissue sarcoma, the major-
ity of deaths occurred within the first five years for high
grade soft tissue sarcoma (Figure 3b and c). The 5-year
RMR according to histological subtypes is shown in
Table 4. The 5- and 10-year MRR according to sex, age,
and level of comorbidity are shown in Table 1. The over-
all risk of dying was 4.4 times (95% CI: 3.9-4.9) higher
for the soft tissue sarcoma patients within the first five
years after diagnosis, compared with the general com-
parison cohort, while ‘only’ 1.6 times (95% CI: 1.3-2.0)
higher within the subsequent five years. The higher mor-
tality was observed within all age and sex groups, except
for soft tissue sarcoma patients ≥ 60 years, where the risk
of dying five to ten years after diagnosis was equal to that
of the general comparison cohort. The adjusted MRRs
were higher in patients without comorbidity within the
first five years and decreased with an increased level of
Figure 2 Overall mortality for soft tissue sarcoma (STS) patients and the general comparison cohort (a) and relative mortality for soft
tissue sarcoma patients (b) with 95% confidence interval.
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soft tissue sarcoma patients is shown in Figure 4. A ten-
dency towards an increased 0–5 year MRR was observed
in the first third of the study period, however neither the
0–5 nor the 5–10 year MRR changed significantly over
the study period. The 5-year MRR according to treatment
regimens in patients with localized and metastatic disease
is shown in Table 5. The lowest excess mortality was
observed in soft tissue sarcoma patients with localized
disease treated solely with a wide resection, whereas the
highest was observed in patients with untreated metastatic
disease.Figure 3 Relative mortality for soft tissue sarcoma patients according
confidence interval.Relative vs. cancer-specific mortality
The relative and the cancer-specific mortality curves are
depicted in Figure 5. The 5- and 10-year relative mortal-
ity for the entire soft tissue sarcoma cohort was 32.8%
(95% CI: 29.8-36.0) and 36.0% (95% CI: 32.3-39.8), com-
pared to a cancer-specific mortality of 31.3% (95% CI:
28.7-34.1) and 36.7% 95% (CI: 33.9-39.7), respectively.
There was no statistically significant difference between
the 5- and 10-year cancer-specific mortality and the rela-
tive mortality (5-year: 1.5 percentage point (pp) [−2.7-5.7],
p = 0.24, 10-year: −0.7 pp [−5.5-4.1], p = 0.61). The 5- and
10-year relative mortality in soft tissue sarcoma patientsto histological grade (a: low, b: intermediate, c: high) with 95%
Table 4 5-year relative mortality according to histological
subtypes (N = 1246)
N RM, % 95% CI
MFH 300 28.0 21.4-35.2
Liposarcoma 195 18.1 11.3-26.1
Leiomyosarcoma 190 33.4 25.6-41.9
Dermatofibrosarcoma 97 2.1 0.0-9.1
Synovial sarcoma 79 46.4 35.4-58.5
MPNST 78 52.4 40.8-64.5
Fibrosarcoma 53 30.3 18.1-46.0
Rhabdomyosarcoma 35 79.3 64.3-90.9
Angiosarcoma 32 56.8 18.1-75.5
Extraosseous osteosarcoma 25 48.6 27.6-71.4
PNET 25 59.7 41.4-78.5
Epithelioid sarcoma 21 27.9 13.2-52.4
Malignant hemangiopericytoma 20 40.9 21.0-66.3
Extraosseous chondrosarcoma 12 37.5 14.2-71.1
Unclassifiable 48 52.3 36.1-68.8
Others 36 31.5 17.3-50.6
NOTES: Abbreviations: RM relative mortality, CI confidence interval, MFH
malignant fibrous histiocytoma, MPNST malignant peripheral nervesheath
tumour, PNET primitive neuroectodermal tumour. Classified according to the
WHO Classification of tumours of soft tissue and bone 3rd edition, 2002.
Table 5 Adjusted mortality rate ratios according to
treatment-regimes in patients with localized and
metastatic soft tissue sarcoma (N = 1246)
N 5-year adjusted MRR (95% CI)*
Localized†
Wide -Rt 595 3.1 (2.6-3.5)
Wide + Rt 157 4.4 (3.0-6.7)
Intra -Rt 125 3.5 (2.5-4.9)
Intra + Rt 127 4.3 (3.0-6.0)
Rt 12 15.3 (5.4-43.4)
Ch +/−Surg/Rt 57 190.4 (48.6-745.3)
None 15 12.4 (4.7-32.2)
Total 1098 3.8 (3.3-4.3)
Metastatic
Surg/Rt 63 15.7 (10.0-24.7)
Ch +/−Surg/Rt 70 228.4 (85.7-608.7)
None 15 236.1 (32.44-1717.9)
Total 148 25.3 (18.2-35.1)
NOTES: Abbreviations: MRR mortality rate ratio, CI confidence interval,
Wide wide resection, Rt radiotherapy, Intra marginal/intralesional resection,
Ch chemotherapy, Surg surgery. *Adjusted for age, level of comorbidity,
compartmentalization, depth, grade, type, location and size. †Margin missing
in 10 cases.
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22.1-28.5) and 28.2% (95% CI: 24.3-32.3), while the cor-
responding cancer-specific mortality was 23.8% (95% CI:
21.3-26.5) and 29.6% 95% (CI: 26.8-32.6), respectively.
The 5- and 10-year cancer-specific mortality were 1.4 (95%
CI: −2.8-5.7, p = 0.26) higher and 1.3 pp (95% CI: −3.7-6.4,
p = 0.70) lower than the relative mortality in soft tissue sar-
coma patient with localized disease, respectively. In soft tis-
sue sarcoma patients with metastatic disease at diagnosisFigure 4 Temporal trends in 0–5 year (black lines) and 5–10
year (grey lines) mortality rate ratios (MRR) with 95%
confidence intervals (dotted) of 1246 soft tissue sarcoma
patients diagnosed at the Aarhus Sarcoma Centre between
1979 and 2008 adjusted for age, sex, and level of comorbidity.the 5-year relative- and cancer-specific mortality was 89.1%
(95% CI 83.0-93.8) and 88.5% (95% CI 82.3-93.2), increas-
ing to 92.9% (95% CI 87.0-96.7) and 91.2% (95% CI 85.4-
95.4) at 10 years, respectively. No statistically significant
discrepancy between the relative and the cancer-specific
mortality was observed in patients with metastatic di-
sease (5-year: 0.7 pp [−6.3-7.6], p = 0.42, 10-year: 1.7 pp
[−4.5-7.8], p = 0.28). The shape of the relative mortality
curve was similar to the cancer-specific mortality curve
both in the entire cohort as well as in the localized and
metastatic cohort, with the majority of sarcoma deaths oc-
curring within the first 5 years of follow up (Figure 5).Discussion
To our knowledge, this is the first study of relative mor-
tality in soft tissue sarcoma patients using individual
age- and sex-matched comparison cohort from the gen-
eral population. In this population-based cohort study
we found that soft tissue sarcoma was associated with a
higher mortality than the general comparison cohort,
with an overall 5- and 10-year relative mortality of 32.8%
and 36.0%. Soft tissue sarcoma patients had a 4.4 times
higher risk of dying within the first five years after diag-
nosis and a 1.6 times higher risk between five and ten
years, compared with the general comparison cohort.
No statistically significant discrepancy between the rela-
tive and the cancer-specific mortality was found.
Figure 5 Relative (black lines) and cancer-specific mortality (grey lines) for soft tissue patients overall (a) as well as stratified by stage
at diagnosis (b-c) with 95% confidence interval.
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The relative mortality rates in sarcoma according to
histological and anatomical subtypes have recently been
investigated using national life tables [38,39]. Results
from the RARECARE project showed an overall 5-year
relative mortality of 42% in soft tissue sarcoma, when
including all anatomical locations. In comparison, our
study population including only tumours located in the
extremity or trunk wall reported a 5-year relative mor-
tality of 32.0% for soft tissue sarcomas in the limbs and
55.9% for STSs in the superficial trunk [38]. Ng et al. re-
ported the 5-year relative mortality according to histo-
logical type, grade and stage, based on data from the
Surveillance, Epidemiology, and End Results (SEER) da-
tabase [39]. The 5-year relative mortality varied from
5% to 15% in low-grade malignant fibrous histiocytoma
(MFH), liposarcoma and leiomyosarcoma, i.e., the three
most frequent subtypes in our study, compared to our
result of 1.2%. Patients with localized MFH, liposarcoma,
and leiomyosarcoma had 5-year relative mortalities of
20%, 24%, and 10%, respectively, while the correspond-
ing mortalities in patients with metastatic disease were
89%, 88%, and 74%, respectively [39].
The adjusted MRRs according to age, sex and comor-
bidity level have not previously been reported in soft tis-
sue sarcoma; however, our results are in accordance
with findings from other studies [40,41]. Within the first
five years since diagnosis, soft tissue sarcoma patient
had higher mortality than the corresponding populationcomparison cohort, independently of age, sex, and level
of comorbidity. However if soft tissue sarcoma patients
survived beyond the first five years after their diagnosis
their risk of dying compared to the general comparison
cohort varied, with no additional risk for patients ≥60
years and patients with severe comorbidity. This is in
overall consistency with previous reports showing that
85-90% of relapses occur within the first five years and
that patients cured of soft tissue sarcoma, i.e., patients
who do not experience relapses, generally do not have
significantly increased mortality compared to the general
population [2,42-44]. A recent study investigated the
long term survival in soft tissue sarcoma patients who
were alive and event-free more than five years after pri-
mary treatment, and reported 6.1% relapses beyond the
first five years, with an overall survival of 97% [45].
Relative vs. cancer-specific mortality
To our knowledge, the correlation between the relative
and the disease-specific mortality in soft tissue sarcoma
patients has not previously been investigated. The rela-
tive mortality in our study was similar to the estimated
cancer-specific mortality, with discrepancies less than
2 pp in both the overall cohort as well as in patients
with localized and metastatic disease.
The correlation between relative and cancer-specific
mortality has been investigated in other cancers, with vary-
ing results depending on the type of cancer [19,20,46-51].
A study of 2777 breast cancer patients reported a 4 pp
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10 years, while a study of 25,531 gastroinstinal carcinoid
patients reported a 3.9 pp higher cancer-specific mortality
[19,20]. A study comparing relative and cancer-specific
survival in rectal cancer patients, using national life tables
to adjust for baseline mortality, reported a 10-year relative
survival of 66.5% (95% CI 61.3-72.1) and a 10-year cancer-
specific survival of 66.4% (95% CI 62.5-70.5), supporting
that the relative mortality in general is an unbiased, precise
estimate for the cancer-specific survival [48].
Methodological considerations
The major strengths of this study include the large
number of soft tissue sarcoma patients and the use of
population-based, systematically validated data from
the Aarhus Sarcoma Registry [22]. Furthermore, the
use of the Danish health care registries allows for vir-
tually complete follow up, thus limiting the risk of se-
lection bias.
Our study had some limitations. The information on
comorbidity was extracted from an administrative regis-
try, where coding errors may be expected to some ex-
tent. However since data in the National Patient Registry
is registered prospectively and independently of this
study, any misclassifications are expected to be non-
differential.
The relative mortality method relies on internal com-
parability between the cohort of interest (soft tissue sar-
coma patients) and the general comparison cohort, and
violation of this can result in possible bias [52]. Mortality
in the general population can be assessed using either
national life tables or a matched general comparison co-
hort. In either case, the general population from which
the data is acquired is assumed to be free of the disease
of interest, with all excess mortality being due to the
disease; however, when using life tables this is rarely the
case. Although, since soft tissue sarcoma is a very rare
disease, the issue of soft tissue sarcoma patients being
included in the data on which the life tables are derived
is considered minor. The internal comparability in this
study is thus expected to be better than studies using na-
tional life-tables, since patients were matched individu-
ally by age, sex, and geographical region, and patients
with previously diagnosed sarcoma were excluded. Fur-
thermore, since comorbidity is closely related to mortal-
ity, data on previous comorbidity was obtained for both
soft tissue sarcoma patients and general population in-
dividuals and included in the analysis. A high internal
comparability is also supported by the similar distribution
of the medical conditions used in the Charlson Comorbid-
ity Index. Soft tissue sarcoma patients had a larger preva-
lence of ‘Any tumour’ and ‘Metastatic solid tumour’;
however, this might be explained by the aetiology of
some sarcomas, being induced by previous treatment withradio- or chemotherapy. Some studies have reported dif-
ferences in survival according to the social economic sta-
tus in other cancer types; however, this has not been
investigated in soft tissue sarcoma. We did not have data
on social economic status, but since the study was con-
ducted in Denmark where all inhabitants have free access
to health care, we expect any possible confounding due to
this to be minor. However, when using a matched general
comparison cohort to assess the mortality in the general
population there is a potential sampling bias, which is not
present when using life tables.
The cancer-specific method relies on identifying the
‘true’ underlying cause of death, as misclassification of
this can result in possible bias. Even in cases where the
correct immediate cause of death is known, the contri-
bution of the cancer as part of the underlying cause can
be impossible to determine, rendering the distinction
between cancer-specific and non-cancer-specific deaths
meaningless [52]. The impact of the disease, e.g., on public
health, is therefore expected to be better captured using
the relative mortality method than the cancer-specific
method.Conclusion
In this population-based cohort study of soft tissue sar-
coma patients with tumours located in the extremity or
trunk wall, the overall 5- and 10-year relative mortality
was 32.8 and 36.0%. Patients with low grade soft tissue
sarcoma did not have increased mortality compared with
the general population. The relative mortality varied ac-
cording to age, grade, stage of diagnosis, and level of
comorbidity, being highest in younger patients and in pa-
tients without comorbidity. The relative mortality provides
an accurate, unbiased method to differentiate between
cancer-specific and non-cancer-specific deaths. However,
when data on the cause of death is of a sufficient quality,
there is no difference between relative mortality and
disease-specific mortality based on death certificates.Additional file
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